false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
2020 Annual Global Meeting: Virtual
Plenary V: Oral Abstract Presentations
Plenary V: Oral Abstract Presentations
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this session, multiple presenters discussed the results of various clinical trials in the field of ovarian cancer. Dr. Nishikawa presented the findings of the JGOG 3023 trial, which evaluated the efficacy and safety of bevacizumab in Japanese patients with platinum-resistant ovarian cancer. The trial showed that adding bevacizumab to chemotherapy resulted in significantly longer progression-free survival and a greater objective response rate compared to chemotherapy alone. Dr. Rocconi presented the results of a trial evaluating the use of the Vigil vaccine as maintenance therapy in patients with ovarian cancer. The study found that the vaccine was well-tolerated and demonstrated significant improvements in both progression-free survival and overall survival, particularly in patients with homologous recombination proficient tumors. Dr. Alvarez-Sicord presented data from the VELIA trial, which assessed the impact of adding Vigil immunotherapy to standard therapy in patients with advanced ovarian cancer. The study found that adding Vigil vaccine resulted in a significant improvement in recurrent-free survival in patients with homologous recombination proficient tumors. Dr. Friere presented the results of a trial evaluating the use of nirapirib as maintenance therapy in patients with ovarian cancer. The study found that adding nirapirib to belvacizumab improved progression-free survival in both higher and lower risk patients, particularly those with tumor-PRACA mutations or HRD-positive tumors. Finally, Dr. Harter presented data from the PAOLA-1 trial, which assessed the efficacy of maintenance olaparib plus belvacizumab in patients with ovarian cancer. The study found that the combination therapy significantly improved progression-free survival in both higher and lower risk patients, particularly those with tumor-PRACA mutations or HRD-positive tumors. Overall, the findings of these trials suggest that combination therapies and maintenance treatments can improve outcomes for patients with ovarian cancer, particularly in specific subgroups of patients.
Keywords
clinical trials
ovarian cancer
JGOG 3023 trial
bevacizumab
Vigil vaccine
maintenance therapy
homologous recombination proficient tumors
nirapirib
PAOLA-1 trial
combination therapies
Contact
education@igcs.org
for assistance.
×